SciClone Pharmaceuticals (Holdings) Management

Management criteria checks 2/4

SciClone Pharmaceuticals (Holdings)'s CEO is Hong Zhao, appointed in Jun 2020, has a tenure of 3.83 years. total yearly compensation is CN¥17.03M, comprised of 45% salary and 55% bonuses, including company stock and options. directly owns 0.082% of the company’s shares, worth HK$8.99M. The average tenure of the management team and the board of directors is 1.8 years and 3.2 years respectively.

Key information

Hong Zhao

Chief executive officer

CN¥17.0m

Total compensation

CEO salary percentage	45.0%
CEO tenure	3.8yrs
CEO ownership	0.08%
Management average tenure	1.8yrs
Board average tenure	3.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Hong Zhao's remuneration changed compared to SciClone Pharmaceuticals (Holdings)'s earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	CN¥1b
Sep 30 2023	n/a	n/a	CN¥1b
Jun 30 2023	n/a	n/a	CN¥953m
Mar 31 2023	n/a	n/a	CN¥904m
Dec 31 2022	CN¥17m	CN¥8m	CN¥855m
Sep 30 2022	n/a	n/a	CN¥844m
Jun 30 2022	n/a	n/a	CN¥833m
Mar 31 2022	n/a	n/a	CN¥878m
Dec 31 2021	CN¥26m	CN¥7m	CN¥923m
Sep 30 2021	n/a	n/a	CN¥837m
Jun 30 2021	n/a	n/a	CN¥779m
Mar 31 2021	n/a	n/a	CN¥766m
Dec 31 2020	CN¥29m	CN¥7m	CN¥754m
Sep 30 2020	n/a	n/a	CN¥817m
Dec 31 2019	CN¥15m	CN¥6m	CN¥615m

Compensation vs Market: Hong's total compensation ($USD2.35M) is above average for companies of similar size in the Hong Kong market ($USD574.19K).

Compensation vs Earnings: Hong's compensation has been consistent with company performance over the past year.

CEO

Hong Zhao (60 yo)

3.8yrs

Tenure

CN¥17,030,000

Compensation

Mr. Hong Zhao has been President and Chief Executive Officer at SciClone Pharmaceuticals (Holdings) Limited since June 24, 2020 and also serves as its Executive Director since June 24, 2020. Mr. Zhao serve...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Hong Zhao	CEO, President & Executive Director	3.8yrs	CN¥17.03m	0.082% CN¥ 9.0m
Chihwen Shao	VP & Head of Technical Operations and Pharmacovigilance	2.3yrs	no data	no data
Min Jia	VP & Head of Immunization Business Unit	no data	no data	no data
Yansong Chang	VP & GM of Oncology Business Unit	no data	no data	no data
Mingxiang Wu	VP and Head of Market Access & Commercial Operation (MACO) Department	no data	no data	no data
Xiaoning Guo	VP, Head of Research & Development Department and Chief Medical Officer	no data	no data	no data
Lianzong Wu	VP and Head of Registration & Pharmaceutical Affairs Department	no data	no data	no data
Li Mao	VP, GM of Research and Development & Chief Medical Officer	1.8yrs	no data	no data
Min Wu	VP & Chief Business Development Officer	less than a year	no data	no data
Rongrong Pan	Company Secretary	less than a year	no data	0.58% CN¥ 63.2m

1.8yrs

Average Tenure

54yo

Average Age

Experienced Management: 6600's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Hong Zhao	CEO, President & Executive Director	3.8yrs	CN¥17.03m	0.082% CN¥ 9.0m
Daniel Vasella	Non-Executive Director	3.7yrs	CN¥658.00k	no data
Guoen Liu	Independent Non-Executive Director	3.2yrs	CN¥658.00k	no data
Zhenfu Li	Non-Executive Chairman	3.8yrs	no data	no data
Wendy Hayes	Independent Non-Executive Director	3.2yrs	CN¥658.00k	no data
Haixia Wang	Non-Executive Director	2.8yrs	no data	no data
Yi-Hsien Lin	Non-Executive Director	3.2yrs	no data	no data
Ping Chen	Independent Non-Executive Director	3.2yrs	CN¥658.00k	no data
Yushao Gu	Independent Non-Executive Director	3.2yrs	CN¥658.00k	no data

3.2yrs

Average Tenure

60yo

Average Age

Experienced Board: 6600's board of directors are considered experienced (3.2 years average tenure).

SciClone Pharmaceuticals (Holdings) Management

Management criteria checks 2/4

Key information

Recent management updates

Less than half of directors are independent

SciClone Pharmaceuticals (Holdings) Limited, Annual General Meeting, Jun 18, 2024

Sciclone Pharmaceuticals (Holdings) Limited Announces Executive Changes

Sciclone Pharmaceuticals (Holdings) Limited Announces Retirement of SHI Cen as Non-Executive Director

SciClone Pharmaceuticals (Holdings) Limited Appoints Lin Shirley Yi-Hsien as Member of the Audit Committee

Sciclone Pharmaceuticals (Holdings) Limited Announces Resignation of Ms. Li Quan as Non-Executive Director and A Member of the Audit Committee of the Board

Recent updates

Less than half of directors are independent

SciClone Pharmaceuticals (Holdings) Limited, Annual General Meeting, Jun 18, 2024

Full year 2023 earnings released: EPS: CN¥1.83 (vs CN¥1.27 in FY 2022)

Sciclone Pharmaceuticals (Holdings) Limited Announces Executive Changes

SciClone Pharmaceuticals (Holdings) Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Investor sentiment improves as stock rises 21%

Investor sentiment improves as stock rises 15%

SciClone Pharmaceuticals (Holdings) Limited Announces Phase III Clinical Trial of Vaborem® Completed Subject Enrollment in China

Investor sentiment improves as stock rises 15%

First half 2023 earnings released: EPS: CN¥1.00 (vs CN¥0.79 in 1H 2022)

SciClone Pharmaceuticals (Holdings) Limited to Report First Half, 2023 Results on Aug 17, 2023

SciClone Pharmaceuticals (Holdings) Limited Announces First Subject Dosed in Phase III Clinical Trial of Vaborem in China

SciClone Pharmaceuticals (Holdings) Limited Approves a Final Dividend for the Year Ended December 31, 2022

Upcoming dividend of HK$0.39 per share at 3.7% yield

Sciclone Pharmaceuticals (Holdings) Limited Announces Retirement of SHI Cen as Non-Executive Director

Full year 2022 earnings released: EPS: CN¥1.27 (vs CN¥1.42 in FY 2021)

SciClone Pharmaceuticals (Holdings) Limited Announces Acceptance of Investigational New Drug Application for Vaborem by Center for Drug Evaluation of the China National Medical Products Administration

SciClone Pharmaceuticals (Holdings) Limited Appoints Lin Shirley Yi-Hsien as Member of the Audit Committee

Sciclone Pharmaceuticals (Holdings) Limited Announces Resignation of Ms. Li Quan as Non-Executive Director and A Member of the Audit Committee of the Board

SciClone Pharmaceuticals (Holdings) Limited Announces NMPA Approval of Biologics License Application of Danyelza (Naxitamab) for Patients with Relapsed or Refractory High-Risk Neuroblastoma in China

Investor sentiment improved over the past week

Insider recently sold HK$218m worth of stock

Less than half of directors are independent

Insider recently sold HK$62m worth of stock

EpicentRx Announces Start of Dosing in China for Global Phase 3 Clinical Trial REPLATINUM (NCT05566041) with Partner SciClone Pharmaceuticals

SciClone Pharmaceuticals (Holdings) Limited Announces First Patient Has Been Dosed in China in RRx-001 Phase III Clinical Trial for the Third Line and Beyond Small Cell Lung Cancer

First half 2022 earnings released: EPS: CN¥0.79 (vs CN¥0.98 in 1H 2021)

SciClone Pharmaceuticals (Holdings) Limited to Report Q2, 2022 Results on Aug 18, 2022

SciClone Pharmaceuticals (Holdings) Limited Announces NMPA Approval of IND of Danyelza (Naxitamab) and GM-CSF in Combination with Irinotecan and Temozolomide in Patients with High-Risk Neuroblastoma with Primary Refractory Disease or in First Relapse

SciClone Pharmaceuticals (Holdings) Limited Appoints MAO Li as Chief Medical Officer

Sciclone Pharmaceuticals (Holdings) Limited Approves Final Dividend for the Year Ended December 31, 2021

Less than half of directors are independent

SciClone Pharmaceuticals (Holdings) Limited to Report Fiscal Year 2021 Results on Mar 24, 2022

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age